Thank you, Guzzi. That is a great question, and it goes to the heart of how the DCVax-Direct program evolved. There’s a common assumption that when a therapy shows survival signal, it should immediately progress to a Phase 2 or Phase 3 trial. But in this case, the answer is more complex, because the original trial design was deliberately constrained, and follow-up was not just a scientific decision, but a strategic one shaped by legal, ethical, and financial architecture.
Let’s begin with what the DCVax-Direct trial actually was. It was a Phase 1, single-arm, dose-escalation study. The goal was not tumor shrinkage or comparative efficacy. The goal was to assess safety, feasibility, and immune activation in patients who had exhausted standard-of-care therapies. These were not borderline cases. These were end-stage patients with inoperable, metastatic tumors, most having failed chemo, checkpoint inhibitors, or radiation. In this trial, there was no chemotherapy. No checkpoint inhibitors. No systemic agents of any kind. And yet, a single direct injection into one tumor triggered immune activity across the body.
The evidence of efficacy was extraordinary for a Phase 1 trial. Twenty-seven out of thirty-nine evaluable patients were still alive at 18 months, despite the fact that none received systemic therapy. Survival durations reached 48 months or more. Biopsies confirmed T cell infiltration and MHC class presentation. Biomarkers showed that secretion of TNF-a, IL-8, and IL-12p40 correlated with extended survival. These were not inflammation artifacts. They were statistically significant signs of systemic immune engagement from a local injection of dendritic cells.
So why no Phase 3?
Because to run a Phase 3 trial outside of an academic center, you are legally required to offer standard-of-care therapy, which in most solid tumors includes chemotherapy, radiation, or surgical resection. This is not optional. Ethics boards, insurers, and regulators demand it. You cannot offer a pure dendritic cell trial unless you are operating under IRB (Institutional Review Board) protection in an academic setting, where trials are designed as investigator-initiated protocols with patients who explicitly waive standard care. That is how the original DCVax-Direct trial occurred. It was not a commercial trial. It was an academic exploration. And that matters.
If Northwest Biotherapeutics had attempted a full Phase 3 trial in the commercial setting, it would have had to include chemo and/or checkpoint inhibitors, confounding the ability to observe pure dendritic cell effects. Worse, it would have cost tens of millions of dollars. A full multi-site, randomized Phase 3 trial for solid tumors would require:
• Dozens of enrolling centers
• Hundreds of patients
• Manufacturing scale across multiple cryogenic batches
• FDA and IRB monitoring at each location
• Control arms with cytotoxic therapy
• Long timelines, typically 3 to 5 years
That design would dilute the signal, increase the cost, and delay the timeline beyond regulatory relevance. And ethically, many patients would still be required to receive toxic therapies first, even when they might prefer dendritic options upfront. For DCVax-Direct, a therapy that requires nothing more than a blood draw and intratumoral injection, that barrier is philosophically and scientifically incompatible.
So instead of pursuing a traditional Phase 3, NWBO shifted strategy. They allowed academic centers like Mayo Clinic to carry the torch. Between 2016 and 2022, Mayo conducted several dendritic cell trials using the same mechanism of action, pulsing autologous DCs with tumor lysate, maturing them ex vivo, and injecting them back into the tumor or nearby. These were not labeled as DCVax. But the process mirrored it in every scientific detail. And the trials were already conducted, under IRB protection, free of standard-of-care mandates.
Mayo’s results showed survival benefit in multiple cancers. They did it without chemo, without radiation, without surgery. And because they were an academic institution, they were legally permitted to offer these dendritic therapies as part of structured protocols, even before approval. The real-world evidence they generated is now considered valid under the UK’s SI 87 framework and the FDA’s CNPV program (Commissioner’s National Priority Voucher), which allows for accelerated review using real-world and existing academic data instead of demanding redundant trials.
So what does this mean going forward?
It means the trials have already happened. They just weren’t branded as “DCVax-Direct Phase 2/3.” They were smarter than that. They were targeted. Now that infrastructure is built, and regulatory alignment exists through SI 87 in the UK, ATP in Canada, and CNPV in the US, follow-up trials will likely move faster and with lower regulatory friction. With Flaskworks automation, Eden terrain matching, and AI platforms like IRIS identifying splicing-derived targets, the next-generation DCVax trials will be faster, cheaper, and personalized.
And with NWBO now legally able to combine DCs with immune booster class agents, checkpoint sensitizers, antiviral primers, cytokine drivers, memory codices, and danger signals, the new trials will not just replicate the signal. They will amplify it.
So the answer is:
The reason there was no traditional Phase 2 or Phase 3 is because the system back then wasn’t built to understand what was already in front of it.
The biology was validated.
The trials were done, at Mayo, at UCLA, and under academic protocols that allowed immune effect to be tested without chemotherapy, radiation, or surgical resection.
But the old regulatory frameworks couldn’t process that kind of evidence.
Now they can.
The regulators have changed. SI 87. ATP. CNPV. They recognize immune mechanism. They accept real-world evidence. They reward validation, not just repetition.
And the system is ready.
The trial you’re looking for?
It already happened.
Now the platform is preparing to fire.
Market Data 
Markets 
